Cargando…

Trametinib with and without pazopanib has potent preclinical activity in thyroid cancer

Multikinase inhibitors (MKIs) targeting VEGF receptors and other receptor tyrosine kinases have shown considerable activity in clinical trials of thyroid cancer. Thyroid cancer frequently exhibits activation of the RAS/RAF/MEK/ERK pathway. In other types of cancer, paradoxical ERK activation has eme...

Descripción completa

Detalles Bibliográficos
Autores principales:	BALL, DOUGLAS W., JIN, NING, XUE, PING, BHAN, SHEETAL, AHMED, SHABINA R., ROSEN, D. MARC, SCHAYOWITZ, ADAM, CLARK, DOUGLAS P., NELKIN, BARRY D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2015
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4583528/ https://www.ncbi.nlm.nih.gov/pubmed/26324075 http://dx.doi.org/10.3892/or.2015.4225

Ejemplares similares

Pazopanib and Trametinib as a Synergistic Strategy against Osteosarcoma: Preclinical Activity and Molecular Insights
por: Chiabotto, Giulia, et al.
Publicado: (2020)

The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma
por: Shroff, Rachna T, et al.
Publicado: (2018)

The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma
por: Shroff, Rachna T, et al.
Publicado: (2017)

Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial
por: Urbonas, V, et al.
Publicado: (2019)

Recent advances in the biology and therapy of medullary thyroid carcinoma
por: Nelkin, Barry
Publicado: (2017)

The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo
por: Booth, Laurence, et al.
Publicado: (2017)

Effects of Pazopanib Monotherapy vs. Pazopanib and Topotecan Combination on Anaplastic Thyroid Cancer Cells
por: Di Desidero, Teresa, et al.
Publicado: (2019)

Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer
por: Di Desidero, Teresa, et al.
Publicado: (2015)

MEK inhibition with trametinib is a successful therapy in ganglioglioma
por: Daniel, Eliza Baird, et al.
Publicado: (2020)

Antineoplastic Activity of Pazopanib in Anaplastic Thyroid Cancer in Primary Culture
por: Ferrari, Silvia Martina, et al.
Publicado: (2023)

Preclinical Modeling of Tumor Growth and Angiogenesis Inhibition to Describe Pazopanib Clinical Effects in Renal Cell Carcinoma
por: Ouerdani, A, et al.
Publicado: (2015)

Karonudib has potent anti-tumor effects in preclinical models of B-cell lymphoma
por: Oksvold, Morten P., et al.
Publicado: (2021)

Dabrafenib plus trametinib treatment in patients with anaplastic thyroid carcinoma: an Argentinian experience
por: Bueno, Fernanda, et al.
Publicado: (2023)

Pazolimus: pazopanib plus sirolimus following progression on pazopanib, a retrospective case series analysis
por: Katz, D., et al.
Publicado: (2016)

Trametinib with or without Vemurafenib in BRAF Mutated Non-Small Cell Lung Cancer
por: Joshi, Monika, et al.
Publicado: (2015)

Guillain-Barre Syndrome Secondary to the Use of Dabrafenib and Trametinib for the Treatment of Advanced Thyroid Carcinoma
por: Batra, Jaskaran, et al.
Publicado: (2023)

The curcumin analogue PAC has potent anti-anaplastic thyroid cancer effects
por: Al-Mohanna, Mai, et al.
Publicado: (2023)

Pazopanib for severe bleeding and transfusion-dependent anemia in hereditary hemorrhagic telangiectasia
por: Parambil, Joseph G., et al.
Publicado: (2021)

Case report: Visibly curative effect of dabrafenib and trametinib on advanced thyroid carcinoma in 2 patients
por: Peng, Xue, et al.
Publicado: (2023)

Pazopanib and anti-VEGF therapy
por: Drabkin, Harry A
Publicado: (2010)

Pazopanib and Statin-Induced Rhabdomyolysis
por: Logue, Jennifer M., et al.
Publicado: (2017)

Phototoxic Reaction Induced by Pazopanib
por: Udompanich, Siriorn, et al.
Publicado: (2018)

Tension Pneumothorax: Is it Sarcoma or Pazopanib?
por: Sebanayagam, Vinoja, et al.
Publicado: (2020)

Ocular toxicity due to Trametinib and Dabrafenib
por: Sarny, Stephanie, et al.
Publicado: (2017)

Pazopanib in the management of advanced soft tissue sarcomas
por: Cranmer, Lee D, et al.
Publicado: (2016)

lncRNA HAR1B has potential to be a predictive marker for pazopanib therapy in patients with sarcoma
por: Yamada, Hideharu, et al.
Publicado: (2021)

lncRNA HAR1B has potential to be a predictive marker for pazopanib therapy in patients with sarcoma
por: Yamada, Hideharu, et al.
Publicado: (2021)

Pazopanib and pancreatic toxicity: a case report
por: Russano, Marco, et al.
Publicado: (2015)

Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions
por: King, Alastair J., et al.
Publicado: (2013)

Co-Targeting MAP Kinase and Pi3K-Akt-mTOR Pathways in Meningioma: Preclinical Study of Alpelisib and Trametinib
por: Mondielli, Gregoire, et al.
Publicado: (2022)

The impact of a 1‐hour time interval between pazopanib and subsequent intake of gastric acid suppressants on pazopanib exposure
por: Krens, Stefanie D., et al.
Publicado: (2021)

Dasatinib and Trametinib Promote Anti-Tumor Metabolic Activity
por: Bolf, Eric L., et al.
Publicado: (2023)

Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma
por: Clark, Peter E
Publicado: (2010)

Pazopanib: Approval for Soft-Tissue Sarcoma
por: Nguyen, Diana T., et al.
Publicado: (2013)

Pazopanib for the treatment of soft-tissue sarcoma
por: Heudel, Pierre, et al.
Publicado: (2012)

Pazopanib induced hand-foot syndrome
por: Sundriyal, Deepak, et al.
Publicado: (2015)

Pazopanib-Induced Alopecia, an Underestimated Toxicity?
por: Biondo, Andrea, et al.
Publicado: (2015)

Pazopanib-Induced Severe Acute Pancreatitis
por: Kawakubo, Kazumichi, et al.
Publicado: (2015)

Thrombotic Thrombocytopenic Purpura Associated with Pazopanib
por: Syed, Umer, et al.
Publicado: (2018)

Pazopanib in advanced soft tissue sarcomas
por: Lee, Alex T. J., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_nmop4qpell1brvvvfdddis1jhp